Ifosfamide Shortage Strains Cancer Treatment Nationwide

A nationwide shortage of the chemotherapy drug ifosfamide, tied to quality concerns at its foreign primary manufacturer, is prompting oncologists to seek alternatives.

Updated on Nov. 19, 2026 in Cancer

Photo of unlabeled amber glass medication vials with white caps on a stainless steel pharmacy shelf in a clean hospital pharmacy, with a gap in the row.
Nationwide shortage of the chemotherapy drug ifosfamide, tied to quality concerns at its foreign primary manufacturer, is forcing oncologists to seek alternative treatments. AI Illustration. Upload story photo >

Live Poll

Do you feel confident your doctor can get the medicines you need?

A nationwide shortage of ifosfamide, a prescription chemotherapy drug used to treat testicular cancer, lymphoma and sarcoma, is affecting treatment availability across the United States. The shortage is linked to quality concerns at the foreign primary manufacturer of the drug.

Why it matters

Domestic production of ifosfamide can be made in the U.S., but it is not sufficient to satisfy current demand, leaving patients who depend on the drug exposed to interrupted care. Oncologists are seeking alternative medicines, and the FDA is being asked to identify alternative sources.

The figures available are clinic-level, with Virginia Oncology Associates serving thousands of patients with the affected cancers and keeping ifosfamide in reserve stock. No national inventory count or comparator was reported, and the expected duration of the shortage remains unknown.

The players

Virginia Oncology Associates

A cancer care practice based in Portsmouth, Virginia, that serves thousands of patients with testicular cancer, lymphoma and sarcoma and has kept ifosfamide in reserve to avoid interrupting treatment.

U.S. Food and Drug Administration

The federal agency responsible for regulating drugs in the United States, which oncologists have asked to help identify alternative sources of ifosfamide.

The details

Patients in other parts of the U.S. have had physicians change their treatments because of the shortage, while Virginia Oncology Associates has so far avoided changes by drawing on reserve stock and searching for alternative medicines. The shortage is tied to quality concerns at the foreign primary manufacturer of the drug.

Timeline

  1. November 19, 2026: Local oncologist comments on the ifosfamide shortage are published

Big Picture

The ifosfamide shortage illustrates the broader dependence of U.S. cancer care on generic chemotherapy drugs made by a single foreign primary manufacturer. When that manufacturer's quality problems interrupt supply, domestic production cannot fully fill the gap.

Patients receiving ifosfamide may face changes to their treatment plans if their physician must substitute another medicine. Patients should ask their oncology team whether reserve supply or alternative therapies are available for their care.

The takeaway

Supply disruptions for essential chemotherapy drugs can change treatment for patients quickly, so it is worth asking your oncology team early about backup options. Patients can also raise questions about drug availability at their next appointment.

Further reading

Explore more Cancer coverage to see how drug supply problems are affecting patients and treatment options.

Source note: This article includes information reported by WAVY-TV 10 Hampton Roads.

Live Poll

Do you feel confident your doctor can get the medicines you need?